Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX)
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX)
3 Unpopular Stocks We’re Skeptical Of
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q1 Earnings?
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference...
3 Mid-Cap Stocks We Steer Clear Of
Royalty Pharma’s Q1 Earnings Call: Our Top 5 Analyst Questions
NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: BofA...
Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13% Net cash provided by operating activities of $718 million Raised full year 2026 guidance: Portfolio Receipts expected...
Barchart Research What to Expect from RPRX Earnings RPRX Generated May 5, 2026 Current Price $50.44 EPS Estimate $$1.22 Consensus Rating Strong Buy Average Move 2.39% What Does Royalty Pharma's Revenue...